Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy

Figures & data

Table 1 Baseline characteristics of all subjects

Characteristics	TPTD to DMAb (n=57)	DMAb alone (n=35)	p-value
Age (years)	70.1±8.9	68.4±8.2	0.376
Lumbar spine BMD (g/cm^2)	0.81±0.08	0.75±0.12	0.004
Total hip BMD (g/cm^2)	0.69±0.76	0.65±0.10	0.026
Femoral neck BMD (g/cm^2)	0.64±0.06	0.61±0.09	0.193

Note: Values are mean ± SD.

Abbreviations: BMD, bone mineral density; DMAb, denosumab; TPTD, teriparatide.

Figure 1 Mean percent changes in BMD in the lumbar spine.

Abbreviations: BMD, bone mineral density; DMAb, denosumab; TPTD, teriparatide.

Figure 2 Mean percent changes in BMD in the total hips.

Abbreviations: BMD, bone mineral density; DMAb, denosumab; TPTD, teriparatide.

Figure 3 Mean percent changes in BMD in the femoral necks.

Note: *p=0.004.
Abbreviations: BMD, bone mineral density; DMAb, denosumab; TPTD, teriparatide.

Table 2 Mean percent change in BMD from baseline at 4, 8, 12, and 18 months

Characteristic	4 months	8 months	12 months	18 months
Lumbar spine BMD
TPTD to DMAb	3.21 (0.46)	5.09 (0.48)	5.71 (0.54)	6.55 (0.54)
DMAb alone	3.77 (0.63)	5.24 (0.71)	6.58 (0.73)	7.94 (0.88)
Total hip BMD
TPTD to DMAb	2.34 (0.33)	2.91 (0.44)	3.93 (0.41)	4.59 (0.43)
DMAb alone	2.23 (0.45)	2.49 (0.62)	3.45 (0.72)	3.79 (0.65)
Femoral neck BMD
TPTD to DMAb	2.29 (0.37)	2.49 (0.45)	3.32 (0.38)	3.85 (0.39)*
DMAb alone	1.04 (0.62)	0.81 (0.83)	2.52 (0.71)	1.68 (0.67)*

Notes: Values are mean percent change (SEM).

* p=0.004.

Abbreviations: BMD, bone mineral density; DMAb, denosumab; TPTD, teriparatide.